A phase I comparative postcoital testing study of three concentrations of C31G
- 30 September 2004
- journal article
- clinical trial
- Published by Elsevier in Contraception
- Vol. 70 (3) , 227-231
- https://doi.org/10.1016/j.contraception.2004.02.001
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol IIContraception, 2004
- Male tolerance study of 1% C31GContraception, 2004
- Safety of single daily use for one week of C31G HEC gel in womenContraception, 2002
- Microbicides—evaluating multiple formulations of C31GContraception, 2002
- Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfateAntiviral Research, 1999
- A phase I study of femcap® used with and without spermicideContraception, 1997
- The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitroAntimicrobial Agents and Chemotherapy, 1997
- Lea's Shield®: A study of the safety and efficacy of a new vaginal barrier contraceptive used with and without spermicideContraception, 1996
- Assessment of the anti-microbial agent C31G as a spermicide: Comparison with nonoxynol-9Contraception, 1996
- Lea's Shield®: A phase I postcoital study of a new contraceptive barrier deviceContraception, 1995